Pharmaceutical Substances - Version 4.13
The version 4.13 of Pharmaceutical Substances was launched in October 2022.
While we are slowly getting used to living in a COVID world, we get reminded that other viruses such as monkeypox and HIV are important disease drivers as well. Fortunately, also in these cases, a number of pharmaceutical substances help us fight these viruses.
Release 4.13 of Pharmaceutical Substances covers 16 new APIs and comprises not only some new antivirals but also several new drugs with very novel mechanisms of action.
The update contains Tecovirimat, so far the only FDA- and EMA-approved drug to treat smallpox and monkeypox, Cabotegravir, an HIV integrase inhibitor used in a once-monthly injectable formulation, and Maribavir for the treatment of CMV after transplantation.
Major medical unmet need is addressed by Mavacamten against hypertrophic cardiomyopathy and Finerenone to treat chronic kidney disease. The update also contains new treatments in dermatology with Abrocitinib and Trifarotene, in cancer with Umbralisib, and in sleeping disorders with Daridorexant.
Furthermore, two new peptide drugs, Tirzepatide, a potential multiblockbuster for the treatment of type 2 diabetes and obesity as well as Dasiglucagon, a hypoglycemia rescue therapy, are described.
This latest release also contains Berotralstat, Cefiderocol, Cenobamate, Ibrexafungerp, and Lactitol for various indications.
Prof. Axel Kleemann, Prof. Bernhard Kutscher, Dr. Dietmar Reichert, Dr. Martin Bossart
16 New APIs
Contact
Thieme Chemistry Marketing Phone:+49-711-89310 E-Mail
